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N. S. Hari Narayana Moorthy*a and Vasanthanathan PoongavanambYellow fever is one of the virus-infected diseases spread through
mosquitoes and kills more than thirty thousand people every year.
Although a large number of compounds have been reported, none of
the drugs have yet been approved for clinical use. In the process of
drug development against yellow fever virus (YFV), in the present
investigation, we have developed eﬃcient classiﬁcation models based
on a large dataset (309 compounds) compiled from the ChEMBL
database. The Na¨ıve Bayes method as implemented in the KNIME
platform was used for the classiﬁcation analysis. The best models
obtained using the combined dataset show accuracy of >90% on the
test set prediction (Matthew's correlation coeﬃcients of >0.7). All the
models developed in this study could be applicable for virtual
screening of yellow fever virus inhibition.Introduction
The yellow fever virus (YFV) is a member of the Flaviviridae
family and this family contains hepatitis C virus (HCV), dengue
virus (DENV), West Nile virus (WNV), Japanese encephalitis
virus (JEV), tick-borne encephalitis virus (TBEV) and bovine viral
diarrhoea virus (BVDV).1,2 These viruses are classied into three
genera: avivirus, hepacivirus, and pestivirus. YFV is one of the
mosquito-borne avivirus which causes the acute viral infection
called yellow fever (YF). Flaviviruses are small, enveloped RNA
viruses responsible for the above mentioned clinical diseases in
humans. These viruses share similar genomic organization and
replication strategies and are transmitted by arthropods and
mosquitoes to humans and birds.2–4 YFV majorly aﬀects the
tropical areas of South America and Africa and this virus causesFaculdade de Cieˆncias, Universidade do
69-007 Porto, Portugal. E-mail: hari.
.pt
acy, University of Southern Denmark,
rk
tion (ESI) available. See DOI:
hemistry 2015nearly 200 000 new infections and 30 000 deaths every year.5,6
Since 1980, number of cases for YFV infection has been
increased, due to the frequent migration of people, less
immune, most people living in cities and climate changes.
According to WHO, severe cases of this infection may cause
fatality which is more than 50%. Eventhough the YFV rate has
been increased over the last 10 years, due to the reasons stated
above.1,7 YFV is an enveloped virus with polyprotein of over
350 kDa, encoded by a single and positive stranded RNA
genome. The non-structural NS3 serine protease (non-structural
protein part in aviviridae family) present in the virus is
essentially acts for viral replication (maturation of the viral
polyprotein) and an attractive target for antiviral drug
discovery.1,2,8,9
Presently, only common antiviral drugs are being used for
the treatment of YFV infection and no specic chemothera-
peutic agents are available for any of these aviviral infections
including yellow fever. Still, there is single drug has not yet been
approved for eﬀective against YFV treatment; however anti-YFV
vaccine (17D) is available to prevent this disease. However, this
live-attenuated 17D vaccine has shown to cause wild-type
disease and systemic infections in a subset of patients.1,10 It
reveals that the antiviral chemotherapeutics would be inex-
pensive, stable, safe and would have eﬃcient when adminis-
tered before and aer virus infection and can be broadly active
against a range of viruses.1
In order to discover novel molecules, virtual screening of
large database or knowledge based drug design like compu-
tational methods are appropriate. From extensive literature
analysis on this target, revealed that there are only a limited
number of in silico studies have been reported on aviviridae
family viruses (including YFV). A computational based
screening analysis on NCI library has been reported to iden-
tify novel aviviral inhibitors using n-octyl-b-D-glucoside
(b-OG) binding pocket of dengue E protein. The b-OG pocket
is an ideal target for structure based design of potential
antiviral agents, because the ligand complex could change the
conformational equilibrium associated with the hinge angleRSC Adv., 2015, 5, 14663–14669 | 14663
Fig. 1 Parent structure of the compounds considered for the present
investigation.
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View Article Online(interferes with the fusion of the viral envelope with the host
cell membrane) and inhibit virus maturation. They reported
three compounds as signicant hit for YFV inhibitory activity
through structure based virtual screening and cell based
assay methods. On account of these templates, a series of
molecules were constructed by them as YFV inhibitors
through structural modication.11–13 The computational
studies such as molecular docking and 3D-comparative
molecular similarity analysis-quantitative structure activity
analysis (3D-CoMSIA-QSAR) were applied on the ChEMBL
database to identify signicant N-substituted indole based
HCV replication inhibitors. The relative eld contributions of
27.6%, 42.1% and 30.3% for steric, hydrophobic and H-bond
acceptor elds, respectively were applied to the CoMSIA
analysis. The QSAR model validation statistics such as Rtest
2
and Rm
2 exhibited a value of 0.727 and 0.635 respectively. The
docking studies of the molecules on HCV revealed that the
indole moiety in the active compounds oriented to the
binding site responsible for group of water molecules located
(inactive compounds have diﬀerent orientation). Interest-
ingly, the active and the inactive compounds reported to
possess equal docking scores.14 The molecular modelling
(homology modelling and docking) study was reported on the
development of fusion inhibitors on ectodomain of TBEV E
protein in virus. The b-OG pocket of the homology model
(open state) was used for the virtual screening, which iden-
tied 89 compounds as hit from substituted 1,4-dihydropyr-
idines and pyrido[2,1-b][1,3,5]thiadiazines containing data
set. Experimental results on the identied hits showed that 17
compounds had signicant inhibition against diﬀerent
viruses (TBEV, Powassan virus, or Omsk haemorrhagic fever
virus).15 Docking and pharmacophore studies were reported
for some avivirus inhibitors by Tonelli et al. against BVD
virus. The pharmacophore results showed that 98% chance
for the best pharmacophore hypothesis to represent a true
correlation in the training set activity. Docking and multiple
alignments of RNA virus proteins showed that the active
compounds target eﬀectively the BVDV RNA-dependent
RNA-polymerase (RdRp), which shares some structural simi-
larity with HCV RdRp.16–18 On account of the above state-
ments, in the present investigation, we have used a set of
literature compounds that inhibit the YFV to develop the
classication models using the Na¨ıve Bayes method as
implemented in the KNIME platform.19–21
Computational methods and materials
A data set of 379 YFV inhibitors was retrieved from the
ChEMBL database (https://www.ebi.ac.uk/chembl/)
(composed mainly from six journal literatures).11,16–18,22,23
Each dataset has diﬀerent parent structures, which are
provided in Fig. 1. Before the datasets used for the classi-
cation study, each dataset was manually checked and curated,
which includes removal of salts, generation of 3D structures,
energy minimization using OPLS2005 force eld. Subse-
quently, thirty 2D physicochemical descriptors of the
compounds were calculated using the CDK tool as it is14664 | RSC Adv., 2015, 5, 14663–14669implemented in the KNIME an open source data analyzer and
integrator.19–21 Classication models were developed using
the Weka data mining soware24 as implemented in KNIME.
The Weka provides a large collection of supervised and
unsupervised machine learning algorithms, attribute selec-
tion and visualization methods.24,25 The dataset was charac-
terized using the SIMCA-P soware (Version 10.5. Umetrics,
Umea, Sweden).Na¨ıve Bayesian theory
Na¨ıve Bayesian classication is a probabilistic supervised
learning method utilizes the Bayes theorem to calculate how
the degree of belief in a proposition changes in accordance to
evidence. Briey, the Bayesian learning works as follows:
before any data has been observed, the expectation as to what
the true relationship between those data can be expressed in a
probability distribution over the assumptions that dene this
relationship. For example, a fruit may be considered to be an
apple if it is red, round and about 300 in diameter. A Naive Bayes
classier considers each of these features to contribute inde-
pendently to the probability that this fruit is an apple,
regardless of the presence or absence of the other
features.21,26,27
The probability model (a conditional model) for a Na¨ıve
Bayesian classier is
p(C|F1,., Fn) (1)
C, a dependent class variable with a small number of
outcomes or classes, conditional on several feature variables F1
through Fn. The conditional distribution over the class variable
C under the independence assumption is:
pðCjF1;.;FnÞ ¼ 1
Z
pðCÞ
Yn
i¼1
pðFijCÞ (2)
where the evidence Z¼ p(F1,., Fn) is a scaling factor dependent
only on F1,., Fn, that is, a constant if the values of the feature
variables are known.This journal is © The Royal Society of Chemistry 2015
Fig. 2 (a) Principal component analysis from ﬁrst 2 PCs, (b) distance to
model plot. The compounds are colored as follows: training set and
non-inhibitors as green dots, training set and inhibitors as blue dots,
test set and non-inhibitor as brown diamonds, and test set and
inhibitor as red circles.
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View Article OnlineThe Gaussian Na¨ıve Bayes classier is applied for a class of
continuous data which are distributed according to a Gaussian
distribution. When the training data contains a continuous
attributes, x and mc, the mean of the values in x associated with
class c, and let sc
2 be the variance of the values in x associated
with class c. The probability density of some value given a
class, p(x ¼ v|c), can be computed by plugging v into the
equation for a normal distribution parameterized by mc, and
sc
2. That is,
pðx ¼ vjcÞ ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2psc2
p e
ðvmcÞ2
2sc2 (3)
Classication model development
In total 16 classication models were developed, models from
1 to 12 represent individual datasets and models 13–16 were
developed from the combined dataset (309 compounds). The
workows were constructed with KNIME platform containing
the CDK nodes. The workow charts used for the analysis are
provided in ESI (Fig. S1†).
Before the models development, the whole dataset was
divided into a training (65%) and a test set (35%) according to
the stratied sampling method, which divides the inhibitors
and non-inhibitors equally in the test and training sets. The
inhibitors and the non-inhibitors were dened according to
diﬀerent activity thresholds (e.g. IC50# 10 mM is inhibitors; IC50
> 10 mM is non-inhibitors). In this study, we explored the quality
of models from diﬀerent activity thresholds, e.g. 10, 30, 50 and
100 mM. However, models developed from the activity thresh-
olds 10 and 100 mM were not discussed due to unbalanced
distribution of inhibitors and non-inhibitors in the datasets,
which leads to insignicant predictions (results are provided in
the ESI (Table S1†)). Therefore, models from 30 and 50 mM are
presented and discussed.
Assessment of classication models
Confusion matrix from each classication model was used to
calculate various statistical parameters to assess the quality of
models. Statistical parameters used in this study are sensitivity
(true positive rate), specicity (true negative rate), G-mean,
Matthew's correlation coeﬃcient (MCC) and overall accuracy.
Sensitivity ¼ TP
TPþ FN (4)
Specificity ¼ TN
TNþ FP (5)
G-mean ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sensitivity specificity
p
(6)
MCC ¼ ðTP TNÞ  ðFP FNÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðTPþ FPÞðTPþ FNÞðTNþ FPÞðTNþ FNÞ
p (7)
Accuracy ¼ ðTPþ TNÞðTNþ FNþ TNþ FPÞ (8)
F -measure ¼ precision sensitivity
precisionþ sensitivity (9)This journal is © The Royal Society of Chemistry 2015Here, TP, TN, FP and FN denote true positive, true negative,
false positive and false negative respectively. The accuracy is the
proportion of correctly predicted positives and negatives. The
F-measure is a measure of a test's accuracy. Sensitivity and
specicity measure the proportion of actual positives and
negatives which are correctly identied, respectively. The
geometric mean (G-mean) evaluates the degree of inductive bias
in terms of a ratio of positive accuracy and negative accuracy
and this term is used to check how well the model is able to
predict two classes. Matthew's correlation coeﬃcient (MCC)
indicates the degree of the correlation between the actual and
predicted classes. It ranges from 1 to +1 and is generally
regarded as a good measure of the quality of the binary
classication.28–30Results and discussion
Characterization of dataset
A principal component analysis (PCA) was performed to check
possible presence of clusters, outliers, similarities or
dissimilarities, distribution of inhibitors and non-inhibitors
in the training and test set in the physicochemical space.
First two principal components from 24 CDK 2D-descriptors
explain 79% of variance in the data set. The score plot from
PCA shows (Fig. 2a) that the diversity of dataset is satisfacto-
rily reected in the training set and there are no distinct
clusters in the dataset. There are some distinct outliers were
observed (distance to model plot is provided in Fig. 2b),RSC Adv., 2015, 5, 14663–14669 | 14665
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View Article Onlinehowever there is no structural similarity within this class of
compounds. It was observed from the loading plot (ESI
Fig. S2†) that most of the inhibitors are highly inuenced by
the topological polar surface area (TPSA) and polar bonds.
This reveals that non-inhibitors are relatively more hydro-
phobic than inhibitors.Fig. 4 Examples of misclassiﬁed compounds in the test set.Construction of classication models
Na¨ıve Bayes based classication models for YFV inhibition was
developed using a set of 24 descriptors. Descriptors used for the
model development were selected from the BestFirst attribute
selection method provided in the Weka soware. The quality of
the models for each dataset was compared in terms of MCC of
test set. Overall KNIME based workow is provided in Fig. 3. In
general, all 6 datasets (activity threshold 30 mM) perform equally
well and an overall accuracy of the test set is >75%.
The quality of model was better for all the dataset in terms
of MCC which found to be larger than 0.6, except for dataset
2, which performs very poor (0.11). This poor performance
was due to the fact that there were only two non-inhibitors,
which were predicted as inhibitors because of not only
sharing of common scaﬀolds as positive but also shares
similar structural patterns. This is exemplied in the Fig. 4.
In addition, we developed models with activity threshold of
50 mM and this leads to overall improvements in the quality of
the model in all datasets. Summary of the model quality is
provided in the Table 1. Models derived from all the datasets
are statistically signicant (MCC and G-mean values > 0.7). In
the same way, the F-score or F-measure also describes the
signicance of the analysed data set. It gives the values >0.8
for all the data set explain that the descriptors used in the
models classied the data set signicantly. The other statis-
tical parameters such as sensitivity and specicity showed theFig. 3 Overall classiﬁcation workﬂow is shown and various task nodes a
14666 | RSC Adv., 2015, 5, 14663–14669values >0.75, except for the model 3 and 7 (provided the
values little less than 0.75).Models from the combined dataset
Although the models obtained from diﬀerent datasets were
signicantly predictive, future prediction might be insig-
nicant due to low diversity as each dataset contains unique
series of compounds. Thus, it would be interesting to see the
prediction ability by combining all the datasets into one. Out
of 379 compounds, 70 compounds (mainly Krecˇmerova´
et al.22) was used as a test set and the remaining datasets
were combined into one in order to train the model. Overall,
the activity threshold 50 mM has yielded a relatively good
accuracy. The models developed from other activity thresh-
olds (10 and 30 mM) were eﬃcient to predict inhibitors
(>90%) compared to non-inhibitors (65%). However, most
of the models were suﬀered from an imbalanced class
distribution which was reected in the quality of the model.
It is highly important to have models that are able to predictre highlighted, including the results output.
This journal is © The Royal Society of Chemistry 2015
Table 1 Summary of models for individual dataset (test set prediction)a
Dataset Models ActThrd
Confusion matrix
Sens. Spec. ROC G-mean F-measure MCC Accu.TP FN TN FP
1 1 30 16 2 6 1 0.89 0.86 0.86 0.87 0.91 0.72 0.88
2 50 14 1 10 0 0.93 1.00 1.00 0.97 0.97 0.92 0.96
2 3 30 11 1 0 2 0.92 0.00 0.91 0.00 0.88 0.11 0.79
4 50 8 1 5 0 0.89 1.00 0.88 0.94 0.94 0.86 0.93
3 5 30 22 0 1 0 1.00 1.00 0.52 1.00 1.00 1.00 1.00
6 50 19 2 1 1 0.90 0.50 0.92 0.67 0.93 0.34 0.87
4 7 30 19 1 4 1 0.95 0.80 0.52 0.87 0.95 0.75 0.92
8 50 10 5 10 0 0.67 1.00 0.92 0.82 0.80 0.67 0.80
5 9 30 18 1 4 0 0.95 1.00 0.88 0.97 0.97 0.87 0.96
10 50 16 1 6 0 0.94 1.00 0.83 0.97 0.97 0.90 0.96
6 11 30 16 2 7 0 0.89 1.00 0.91 0.94 0.94 0.83 0.92
12 50 15 0 6 4 1.00 0.60 0.88 0.77 0.88 0.69 0.84
a ActThrd¼ activity threshold; TP¼ true positive; FN¼ false negative; TN¼ true negative; FP¼ false positive; ROC¼ receiver operating curve; Sens.
¼ sensitivity; Spec. ¼ specicity; MCC ¼ Matthew's correlation coeﬃcient; Accu. ¼ accuracy; F ¼ F-measure.
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View Article Onlinecorrectly both classes in a reasonably balanced manner and
not only correctly predicts one of the classes with high
accuracy.
Therefore, new models were constructed based on a set of
309 compounds (Krecmerova´ et al. dataset was excluded), in
which 200 compounds were used as a training set and the
remaining 109 compounds were used as a test set. The
models for each activity thresholds (10, 30, 50 and 100 mM)
were developed. These models provided the sensitivity andFig. 5 Final KNIME workﬂow for the classiﬁcation model of yellow feve
Table 2 Statistical parameters for the combined data set modelsa
Models
Confusion matrix
Sensitivity SpeciTP FN TN FP
13b 101 0 5 3 1.00 0.63
14c 85 2 12 10 0.98 0.55
15d 67 6 28 8 0.92 0.78
16e 47 1 61 0 0.98 1.00
a TP ¼ true positive; FN ¼ false negative; TN ¼ true negative; FP ¼ false
coeﬃcient; F ¼ F-measure. b Model from activity threshold at 10 mM. c M
at 50 mM. e Model from activity threshold at 100 mM.
This journal is © The Royal Society of Chemistry 2015specicity values of >0.9, however the specicity values have
signicantly decreased for the models 13 and 14. Overall, the
model 15 from activity threshold at 50 mM gives the better
performance over the other thresholds. The model (15)
predicts 92% of inhibitors and 78% of non-inhibitors
correctly with good coeﬃcient (MCC ¼ 0.71), and the
quality is also reected in the high G-mean score (0.84)
(Table 2).r inhibition.
city ROC G-mean F-measure MCC Accuracy
0.81 0.79 0.97 0.78 0.99
0.76 0.73 0.89 0.63 0.93
0.85 0.84 0.87 0.71 0.91
0.99 0.99 0.99 0.98 0.99
positive; ROC ¼ receiver operating curve; MCC ¼ Matthew's correlation
odel from activity threshold at 30 mM. d Model from activity threshold
RSC Adv., 2015, 5, 14663–14669 | 14667
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View Article OnlineOpen source KNIME workow for YFV
In order to provide the YFV inhibition model to the medicinal
chemistry community, model 15 is implemented into KNIME
workow as shown in Fig. 5. The workow can be directly
downloaded into any workstation having KNIME soware
package installed. There is no prerequisite before running
KNIME, as most of the cheminformatics nodes are already
available in the KNIME suite. The KNIME workow reads the
molecules (2D or 3D conformation) in sdf le format (.sdf)
and other procedures are automated. Subsequently, it
produces output les (xls or csv) containing predictions with
statistical signicance.Conclusion
The number of cases of YFV infection has signicantly been
increased in the recent years; although the vaccines are
available for YFV infection, an inexpensive, safe and eﬀective
chemotherapeutic agent is still needed for wide usability. In
the present study, the KNIME based classication models were
developed using the existing YFV inhibitors from the ChEMBL
database. The best classication model is able to discriminate
>90% of inhibitors from non-inhibitors with an overall accu-
racy of >90%. Subsequently, the best model is implemented in
the KNIME workow which could be used as a virtual
screening workow to screen novel molecules for the YFV
inhibitory activity.Acknowledgements
The authors are thankful to ChemAxon, KNIME and OpenEye
scientic soware for providing a free academic license.References
1 J. G. Julander, Antiviral Res., 2013, 97, 169–179.
2 S. Agnihotri, R. Narula, K. Joshi, S. Rana and M. Singh,
Bioinformation, 2012, 8(3), 123–127.
3 K. Lohr, J. E. Knox, W. Y. Phong, N. L. Ma, Z. Yin, A. Sampath,
S. J. Patel, W. L. Wang, W. L. Chan, K. R. Ranga Rao,
G. Wang, S. G. Vasudevan, T. H. Keller and S. P. Lim, J.
Gen. Virol., 2007, 88, 2223–2227.
4 C. C. Pacca, A. A. Severino, A. Mondini, P. Rahal,
S. G. P. Davila, J. A. Cordeiro, M. C. L. Nogueira,
R. V. M. Bronzoni and M. L. Nogueira, Virus Genes, 2009,
38, 224–231.
5 J. Lescar, D. Luo, T. Xu, A. Sampath, S. P. Lim, B. Canard and
S. G. Vasudevan, Antiviral Res., 2008, 80, 94–101.
6 G. Chatelain, Y. Debing, T. D. Burghgraeve, J. Zmurko,
M. Saudi, J. Rozenski, J. Neyts and A. V. Aerschot, Eur. J.
Med. Chem., 2013, 65, 249–255.
7 Global alert and response (GAR)-Yellow fever, World Health
Organization, http://www.who.int/csr/disease/yellowfev/en/.
8 T. J. Chambers, A. D. Droll, Y. Tang, Y. Liang, V. K. Ganesh,
K. H. M. Murthy and M. Nickells, J. Gen. Virol., 2005, 86,
1403–1413.14668 | RSC Adv., 2015, 5, 14663–146699 D. A. Droll, H. M. K. Murthy and T. J. Chambers, Virology,
2000, 275, 335–347.
10 M. G. V. Santana, P. C. C. Neves, J. R. Santos, N. S. Lima,
A. A. C. dos Santos, D. I. Watkins, R. Galler and
M. C. Bonaldo, Virology, 2014, 452–453, 202–211.
11 Z. Li, M. Khaliq, Z. Zhou, C. B. Post, R. J. Kuhn and
M. Cushman, J. Med. Chem., 2008, 51, 4660–4671.
12 Y. Modis, S. Ogata, D. Clements and S. C. A. Harrison, Proc.
Natl. Acad. Sci. U. S. A., 2003, 100, 6986–6991.
13 Y. Zhang, W. Zhang, S. Ogata, D. Clements, J. H. Strauss,
T. S. Baker, R. J. Kuhn and M. G. Rossmann, Structure,
2004, 12, 1607–1618.
14 E. Vrontaki, G. Melagraki, T. Mavromoustakos and
A. Afantitis, Methods, 2015, 71, 4–13.
15 D. I. Osolodkin, L. I. Kozlovskaya, G. G. Karganova,
E. V. Dueva, V. A. Palyulin, N. S. Zerov and
V. M. Pentkovski, J. Cheminf., 2012, 4(suppl. 1), P29.
16 M. Tonelli, V. Boido, C. Canu, A. Sparatore, F. Sparatore,
M. S. Paneni, M. Fermeglia, S. Pricl, L. Colla, L. Casula,
C. Ibba, D. Collu and R. Loddo, Bioorg. Med. Chem., 2008,
16, 8447–8465.
17 M. Tonelli, I. Vazzana, B. Tasso, V. Boido, F. Sparatore,
M. Fermeglia, M. S. Paneni, P. Posocco, S. Pricl, P. L. Colla,
C. Ibba, B. Secci, G. Collu and R. Loddo, Bioorg. Med.
Chem., 2009, 17, 4425–4440.
18 M. Tonelli, M. Simone, B. Tasso, F. Novelli, V. Boido,
F. Sparatore, G. Paglietti, S. Pricl, G. Giliberti, S. Blois,
C. Ibba, G. Sanna, R. Loddo and P. L. Colla, Bioorg. Med.
Chem., 2010, 18, 2937–2953.
19 S. Beisken, T. Meinl, B. Wiswedel, L. F. de Figueiredo,
M. Berthold and C. Steinbeck, BMC Bioinf., 2013, 14, 257.
20 M. R. Berthold, N. Cebron, F. Dill, T. R. Gabriel, T. Ko¨tter,
T. Meinl, P. Ohl, C. Sieb, K. Thiel and B. Wiswedel,
KNIME: The Konstanz Information Miner, in Studies in
classication, data analysis, and knowledge organization
(GfKL 2007), Springer-Verlag, Heidelberg-Berlin, 2007.
21 M. R. Berthold, N. Cebron, F. Dill, G. Di Fatta, T. R. Gabriel,
F. Georg, T. Meinl, P. Ohl, C. Sieb and B. Wiswedel, KNIME-
The Konstanz Information Miner ACM SIGKDD Explorations
Newsletter, ACM, New York, USA, 2009, p. 31.
22 M. Krecˇmerova´, A. Holy, A. Pıskala, M. Masojıdkova,
G. Andrei, L. Naesens, J. Neyts, J. Balzarini, E. De Clercq
and R. Snoeck, J. Med. Chem., 2007, 50, 1069–1077.
23 M. Mazzei, E. Nieddu, M. Miele, A. Balbi, M. Ferrone,
M. Fermeglia, M. T. Mazzei, S. Pricl, P. L. Colla,
F. Marongiu, C. Ibbac and R. Loddo, Bioorg. Med. Chem.,
2008, 16, 2591–2605.
24 M. Hall, E. Frank, G. Holmes, B. Pfahringer, P. Reutemann
and I. H. Witten, The WEKA data mining soware: an
update, SIGKDD Explorations Newsletter, 2009, 11, 10–18.
25 G. Melagraki and A. Afantitis, Chemom. Intell. Lab. Syst.,
2013, 123, 9–14.
26 A. McCallum and K. A. Nigam, A comparison of event models
for Naive Bayes text classication, AAAI-98 workshop on
learning for text categorization, Madison, Wisconsin, USA,
July 1998, vol. 26–27, p. 752.This journal is © The Royal Society of Chemistry 2015
Communication RSC Advances
Pu
bl
ish
ed
 o
n 
23
 Ja
nu
ar
y 
20
15
. D
ow
nl
oa
de
d 
by
 S
yd
da
ns
k 
U
ni
ve
rs
ite
tsb
ib
lio
te
k 
on
 0
6/
11
/2
01
7 
08
:5
4:
13
. 
View Article Online27 K. Chai, H. T. Hn and H. L. Chieu, Bayesian online classiers
for text classication and ltering, Proceedings of the 25th
annual international ACM SIGIR conference on Research and
Development in Information Retrieval, August 2002, pp. 97–
104.
28 N. S. H. N. Moorthy, S. F. Sousa, M. J. Ramos and
P. A. Fernandes, RSC Adv., 2014, 4(106), 61624–61630.This journal is © The Royal Society of Chemistry 201529 N. S. H. N. Moorthy, N. M. F. S. A. Cerquira, M. J. Ramos and
P. A. Fernandes, Chemom. Intell. Lab. Syst., 2015, 140, 102–
116.
30 K. K. Chohan, S. W. Paine, J. Mistry, P. Barton and
A. M. Davis, J. Med. Chem., 2005, 48, 5154–5161.RSC Adv., 2015, 5, 14663–14669 | 14669
